Lentinula edodes as a Source of Bioactive Compounds with Therapeutical Potential in Intestinal Inflammation and...

Area of Science:

• Mycology
• Immunology
• Gastroenterology
• Oncology

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a growing global health concern.
• Chronic intestinal inflammation is a significant risk factor for colorectal cancer (CRC).
• Existing IBD and CRC treatments face challenges with patient resistance and severe side effects.

Purpose of the Study:

• To explore the potential of bioactive substances from Lentinula edodes (shiitake mushroom) as a therapeutic agent for IBD and CRC.
• To review the immunomodulatory and anticancer properties of Lentinula edodes, particularly its glucans.

Main Methods:

• In vitro and animal model studies investigating the effects of L. edodes bioactive compounds.
• Analysis of clinical trial data on L. edodes compounds in combination with chemotherapy for CRC.
• Review of research on the impact of L. edodes glucans on gut microbiome and immune responses.

Main Results:

• L. edodes glucans demonstrate anti-inflammatory, antioxidant, and apoptosis-inducing effects on cancer cells.
• These compounds have shown potential in reducing tumor angiogenesis and improving gut barrier function.
• Clinical trials indicate improved prognosis for CRC patients when L. edodes compounds are used with chemotherapy.
• L. edodes glucans enhance microbial diversity and interferon-gamma production.

Conclusions:

• Bioactive compounds from Lentinula edodes, especially glucans, possess therapeutic potential for inflammatory bowel disease and colorectal cancer.
• Further research, including randomized controlled trials and long-term follow-up studies, is necessary to confirm efficacy and elucidate mechanisms of action.